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Abstract 
 
Various recent data point to the heterogeneity of undifferentiated stem cells, which appear 
to be able to exist in alternative states that can interconvert from one to another. The precise 
significance of these ‘sub-states’ remains to be established. It may be that they may represent 
different steps as a stem cell prepares to differentiate so that, while not committed to 
differentiate, cells in some states are more likely to differentiate than those in other states. 
Another possibility is that the sub-states exhibit lineage priming so that cells in one sub-
state might be more likely to differentiate into a particular lineage than cells in another sub-
state at the time when they commit to differentiate. To test these hypotheses it is essential 
to be able to identify and isolate cells in particular sub-states. The phenomenon of ‘culture 
adaptation’ of human ES cells tends to ‘trap’ cells in sub-states in a way that permits their 
isolation. Otherwise, prior to culture adaptation it is thought that some such sub-states may 
exist but only in a transitory way, making it difficult to isolate them. Consequently in this 
project we are utilising the EC cell line NTERA2, which given its oncogenic nature it can be 
regarded as a culture adapted cell line. We are also employing the well characterised, 
culture adapted, human ES cell line, H7.S6, together with several newly derived antibodies 
that mark the stem cell state, in conjunction with other established markers, to define, 
isolate and characterise sub-states that may exist within the undifferentiated stem cell 
compartment of human ES cells. 
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Chapter 1 
1 Introduction 
1.1 Properties of Stem Cells 
 
Stem cells are a type of cell that are capable of self-renewal, a process by which a cell divides 
and gives rise to another identical cell which retains the capacity to differentiate into 
progenitor cells which later develop into the specialised cells that maintain the tissues and 
organs of a living organism. Embryonic stem cells are derived from the inner cell mass of the 
blastocyst and under appropriate in-vitro conditions they exhibit unlimited undifferentiation 
potential (Evans and Kaufman, 1981; Martin, 1981). Non-embryonic (somatic or adult) stem 
cells are thought to be undifferentiated cells that are found together with differentiated cells 
in a specific tissue or organ. The main function of these adult stem cells is to maintain and 
repair the tissue or organ in which they reside (Valdes Chavarri et al., 2005).  
The importance of stem cells for living organisms lies not only on their ability to give rise to 
all the specialised cell types and organs that make up the organism. Some adult tissues, such 
as the brain, muscle and bone marrow, have discreet populations of stem cells that are able 
to generate replacements for cells that have been lost due to ageing, injury or disease (Graf 
and Stadtfeld, 2008). This has led to their being used in therapies for regenerative medicine. 
Nevertheless, this very ability of stem cells to differentiate into any cell type has also proven 
to be problematic in terms of scientists not being able to control and regulate the mechanisms 
of differentiation. Therefore, much work remains to be done if they are to be used safely in 
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the clinic. In recent years, much work has been done on dissecting the role of particular 
signalling pathways in the differentiation and self-renewal of human pluripotent stem cells. 
Some strategies that have been developed focus on either maintaining cells in an 
undifferentiated state or controlling the particular cell fates that cells can take. An important 
point of focus in the lines of work carried out in the laboratory is on genetic changes in ES 
cells, such as mutation and selection. It has been noted that some of the common changes 
that take place in variant ES cells also occur in EC cells, the malignant counterpart of 
embryonic stem cells (Draper et al., 2004a; Draper et al., 2004b). 
The mechanism of self-renewal is one of the key features of stem cells that may be shared by 
cancer stem cells. It has therefore been proposed that the signalling pathways that regulate 
this process might also be involved in oncogenesis. These signalling pathways include Notch, 
Sonic Hedgehog and Wnt signalling pathways (Taipale and Beachy, 2001). Furthermore, the 
stimulation of TGF-β and FGF signalling constitutes the central strategy for maintaining 
human embryonic stem cells in a state of self-renewal (Galvin-Burgess et al., 2013). However, 
one important common factor for applying methods of signalling pathway 
activation/repression is the fact that it is assumed that every cell in the stem cell population 
is in the same state and thus will respond in a coordinated manner to the exogenous signals 
being applied. Nevertheless, it has recently become apparent that human pluripotent stem 
cell cultures are made up of a heterogeneous mixture of cells. This raises the issue of not 
being able to determine whether all cells will respond in the desired manner to the stimuli 
being applied.  
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1.1.1 Differentiation and heterogeneity 
 
If scientists want to harness the ability of directing the differentiation of stem cells for their 
use in medical therapies, they must first understand how a stem cell decides when and what 
to transform themselves into. However, it has been shown that not all pluripotent stem cell 
lines display the same capacity to differentiate into a specific cell type in vitro. There are 
genetic and epigenetic factors that alter the growth and differentiation properties from one 
cell line to another and that in turn cause heterogeneity within clones (Cahan and Daley, 
2013). 
Stem cell populations, throughout development, display one common feature that defines 
their ability to differentiate into several phenotypes: heterogeneity. This heterogeneity is a 
manifestation of the fluctuations in gene expression of stem cell populations. These 
fluctuations are in turn the basis of the existence of distinct sub-populations of cells within 
the main stem cell population (Bhatia et al., 2013). Another form of heterogeneity could 
simply be due to the presence of early spontaneous differentiated derivatives in cultures. 
Stem cells have been described to fluctuate between pluripotent states in response to the 
expression levels of certain pluripotency genes such as Nanog. ES cells are able to interconvert 
between these states while still remaining uncommitted to differentiate (Burgess-Galvin et 
al., 2013). It has been argued that this heterogeneity mechanism appeared as a means of 
allowing stem cells to respond to cues that induce differentiation while at the same time being 
able to maintain their self-renewal potential (Graf and Stadtfeld, 2008). 
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1.1.2 Regulatory networks of undifferentiation 
 
The culture conditions required to keep ES cells in an undifferentiated state of are quite 
specific and they have been designed to regulate the transcription-factor regulatory networks 
that maintain pluripotency (Othsuka and Dalton, 2008). The main transcription factors that 
regulate this regulatory network are OCT4 (POU5F1), SOX2 and NANOG. The orchestrated 
interaction between these autoregulated transcription factors, together with other 
components, such as the Polycomb group (PcG) chromatin regulators are responsible for 
maintaining lineage specification programmes in a silent and controlled way (Boyer et al., 
2005). 
Recently, it has been shown that the co-expression of these transcription factors in 
pluripotent stem cells prevents commitment to differentiation to any lineage but they 
promote specific fates when they act independently of each other (Thomson et al., 2011). The 
signalling pathways that are involved in directing cells towards a mesendodermal or 
ectodermal fate are also in part calibrated by this pluripotency network of transcription 
factors (Cahan and Daley, 2013). However, perturbations that occur in the pluripotency 
network and that in turn cause some functional differences in pluripotent stem cells might be 
detectable or remain silent at the genetic expression level in the pluripotent state. For 
example, if there is a change in the sensitivity to differentiation signals, it may be because of 
a variable expression of elements of the networks responsible for lineage commitment 
(Cahan and Daley, 2013). Thirty years ago, Evans and Kaufmann anticipated the concept of 
stem cell variability by proposing that there might exist some degree of differentiation ability 
rather than a selective restriction as one possible reason for the different cell type 
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distributions found in teratomas that arise from mouse ES cell subclones (Evans and Kaufman, 
1981). 
 
1.2 Embryonal carcinoma cells 
1.2.1 Basic properties of EC cells 
 
Teratomas and teratocarcinomas are a type of tumour that contains tissue derivatives that 
come from all three germ layers. In humans, they represent a subtype of germ-cell tumours. 
Undifferentiated embryonal carcinoma cells are the elements that confer malignancy to these 
tumours. In mouse, when EC cells are injected to adults, they give rise to tumours, however 
when injected to early-embryos they form differentiated tissues. Unlike EC cells, when ES cells 
are injected into adult mice, they only produce teratomas but not teratocarcinomas 
(Damjanov, 2004).  
The teratocarcinoma experimental system was described in 1967 (Pierce, 1967; Stevens, 
1967). However, Stevens & Little reported in 1954 that male mice from the 129 strain 
developed spontaneous testicular teratomas and teratocarcinomas and these could be 
observed as incipient tumours described as embryoid bodies in the seminiferous tubules of 
the developing gonad at day 13 of embryonic development (Stevens, 1964). Inbred strains of 
mice with high incidence of spontaneous testicular teratocarcinomas were established in 
these studies. These tumours were shown to be transplantable and their origin was traced to 
stem from primordial germ cells in foetal testes. Furthermore, cells from tumours were shown 
to be able to grow in tissue culture. However, it was the demonstration that transplanting a 
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single cell in vivo could give rise to a teratocarcinoma made up of a wide variety of 
differentiated tissues that established the existence of pluripotent tumour (EC) stem cells 
(Kleinsmith and Pierce, 1964). 
The establishment of EC cell cultures led to work on ES cells and offered many advantages 
over the use of the inaccessible mammalian embryo, as they posed a more scalable and 
manipulable experimental system than the mouse embryo. Studies were published in which 
mass cultures of cells from embryoid bodies were isolated to establish clonal cultures (Kahan 
and Ephrussi, 1970; Rosenthal et al., 1970). However, it was two years later when clonal lines 
from well differentiated solid teratocarcinomas were established and they were shown 
differentiate even after prolonged passage in culture (Evans, 1972). 
Embryonal carcinoma cells are derived from teratocarcinomas, which are a malignant type of 
Germ Cell Tumour (GCT). Teratocarcinomas also contain differentiated cells from the three 
embryonic germ layers (Sperger et al., 2003). When transplanted into another tissue or organ, 
embryonal carcinoma cells can produce tumours. 
One of the reasons for their use in research lies in the fact that they can generate normal 
somatic tissue after being injected into a mouse blastocyst (Papaioannou et al., 1975). As 
such, human EC cells might give an insight into the mechanisms that drive human 
development. 
Given the nature of EC cells, their use in research has become widely available. In many 
instances, human EC cell lines provide an advantage over their ES counterparts in terms or 
requiring less attention when growing in culture. The undifferentiated nature of human ES 
cell cultures is quite susceptible to the density under which they are grown. However, most 
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human EC cell lines are able to remain undifferentiated when kept at high density (Andrews 
& Goodfellow, 1980; Andrews, et al., 1982; Andrews, et al., 1987). 
The use of EC cell lines also provides an advantage over the direct use of mouse embryos, 
since EC cells can be cultured as a self-renewing population, thus providing enough quantities 
of material in a straightforward and inexpensive way. Despite the increasing use of human ES 
cell lines since their derivation in 1998(Thomson et al., 1998a); EC cell lines continue to be the 
tool of choice given the insights that have been gained as the best characterised model for 
early human development. 
 
1.2.2 NTERA2/clone D1 
 
The parental NTERA2 cell lines were derived from a mouse xenograft of the Tera-2 cell line. 
Clone D1 of NTERA2 constitutes a pluripotent human testicular embryonal carcinoma cell line 
derived from the parental NTERA2 line (Andrews et al., 1984b).  
The human cell line NTERA2 together with the murine line P19 are amongst the most 
extensively studied EC cell lines. These two cell lines undergo differentiation with retinoic acid 
and neuronal cells are among the most prominent cell type found in the differentiated 
population (Andrews, 1984; McBurney et al., 1982). The Wnt and Notch signalling pathways 
have been shown to be responsible for the regulation of neural differentiation from 
uncommitted precursor cells during embryonic development (Cadigan and Nusse, 1997; 
Weinmaster, 1997). Recently, using NTERA2 cells, these two pathways have been proposed 
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in a tentative model for the maintenance of EC stem cells in an undifferentiated state and 
also for regulating their differentiation (Walsh and Andrews, 2003). 
The ability to proliferate rapidly in vitro and to differentiate into at least two postmitotic cell 
types (Andrews, 1984; Bani-Yaghoub et al., 1999), confers the NTERA2 cell line great potential 
to be an important research tool.  
NTERA2/D1 cells have been shown to undergo differentiation along neuroectodermal 
lineages when exposed to retinoic acid (RA) or hexamethylene bisacetamide (HMBA) 
(Andrews, 1984; Andrews et al., 1984b; Andrews et al., 1990). The importance of establishing 
how these cells respond and control the processes that take place during differentiation was 
highlighted by the fact that, just as with the immune system, the different cell types that are 
present in teratocarcinomas could be characterised by looking at the spectrum of 
differentiation antigens that are expressed on these cells (Andrews, 1988). Boyse and 
colleagues introduced the idea that different subsets of cells in a particular developing system 
(i.e. the immune stystem) could be distinguished by looking at the different range of cell 
surface antigens expressed (Boyse and Old, 1978). These differentiation antigens constitute 
a practical strategy for analysing the different subsets of cells that exist in a heterogeneous 
system and also provide a method for separating the cells in a way that allows their 
developmental relationships to be studied. Amongst those antigens, there may be some that 
play a role in mediating cell-cell interactions, which in turn are important in regulating 
development. 
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1.2.3 Cell surface antigens 
 
The glycolipids expressed by murine and human EC cells are for the most part 
glycosphingolipids with a globo-series carbohydrate core structure (Eppig et al., 1977; 
Willison et al., 1982). Mouse EC cells might present a N-acetyl galctosamine moiety to 
produce an epitope recognised as the Forssman antigen (Stern et al., 1978). Human EC cells 
lack this antigen and instead a globoside is further modified which in turn yields structures 
that bear the epitopes corresponding to the stage-specific embryonic antigens (SSEA3-4) and 
the globo-ABH antigens (Fenderson et al., 1987; Shevinsky et al., 1982). 
SSEA3 was found to be strongly expressed in human EC cells (2102Ep) and soon after, SSEA4 
expression was also detected in these cells (Andrews et al., 1982; Kannagi et al., 1983). 
However, mouse EC cells did not express this antigen (Shevinsky et al., 1982). The positive 
expression of SSEA3/SSEA4 was later found to be quite common in other human EC cell lines 
such as NTERA2 (Andrews et al., 1984b). Likewise, EC cells from human germ cell tumour 
specimens removed from patients during surgery displayed the SSEA3+/SSEA4+ phenotype 
(Damjanov et al., 1982). 
One important aspect of studying the expression of cell surface antigens in EC cells is 
highlighted by the fact that tumours from xeno-transplanted mice with SSEA3/SSEA4 negative 
human TERA-2 (cl. w1) cells, contained cells that expressed these antigens even when 
explanted and passaged in vitro for 3 months (Andrews et al., 1985). It was suggested that 
this phenomenon might involve a type of interrelation between the expression of these 
antigens and EC tumour growth (Andrews, 1988). 
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A notable difference between mouse and human EC cells is that the latter have little or no 
reaction with antibodies that recognise the SSEA1 antigen (Andrews et al., 1982; Damjanov 
et al., 1982; Kannagi et al., 1982; Solter and Knowles, 1978). Nevertheless, the appearance of 
SSEA1 in some human EC-like cell lines has been associated with the cells being in an early 
stage of differentiation (Fenderson et al., 1987). 
There are other EC cell antigens recognised by monoclonal antibodies that have been 
described (Andrews et al., 1984a; Blaineau et al., 1984; Rettig et al., 1985). Two of these, TRA-
1-60; TRA-1-81, have been associated with high molecular weight polypeptides of 
approximately 200,000 and 400,000 respectively (Andrews et al., 1984a). The epitopes 
expressed by this family of high molecular weight protein antigens appear to be restricted to 
human cells, however mouse embryos and murine EC/ES cells have been found not to express 
them (Muramatsu et al., 1978). 
Alkaline phosphatase (ALP) is an enzyme expressed on the cell surface of human EC and ES 
cells in a tissue non-specific form and can be detected by two monoclonal antibodies, TRA-2-
49 and TRA-2-54 (Andrews et al., 1984c; Benham et al., 1981). Two other antigens used 
include TRA-1-85 and CD9. TRA-1-85 reacts with a pan-human antigen known as the blood 
group antigen Ok(a) (Williams et al., 1988). CD9 is down-regulated upon differentiation and 
has been useful in identifying subsets of cells that still reside in the stem cell compartment 
(International Stem Cell et al., 2007; Laslett et al., 2007). 
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1.3 Human ES/EC cell subpopulations 
1.3.1 Stem cell substates 
 
When stem cells respond to cues from different signalling pathways in order to either 
differentiate or self-renew, they express a wide array of surface antigens that can identify a 
cell as being ready for differentiation into a particular lineage or mark the cell for self-renewal 
or even death. 
The decisions that stem cells make in order to differentiate into specific cell lineages is a major 
goal in stem cell biology. The heterogeneity found in progenitor cell populations is a reminder 
that stem cell subsets express different properties such as varying propensities of lineage 
selection upon differentiation. Stem cells are faced with a number of options which include 
self-renewal, differentiation, apoptosis and quiescence. Understanding how the cells select 
and coordinate these various pathways is a key factor in trying to elucidate the causes of 
cancer and also in harnessing their properties for regenerative medicine. 
It is also important to be able to control the heterogeneity present in stem cell populations. 
In this respect, the study of the expression of specific cell surface markers has led to the 
general consensus that SSEA3-4, TRA-1-60, TRA-1-81 conform some of the most important 
and useful markers of undifferentiation. Moreover, it has been suggested that SSEA3 could 
be a sensitive marker of the most primitive state for human ES cells thanks to studies carried 
out on human EC and ES cells (Andrews et al., 1996; Draper et al., 2002; Fenderson et al., 
1987; Henderson et al., 2002). Since human embryonic stem cells can spontaneously 
differentiate in standard culture conditions, the heterogeneous expression of SSEA3 observed 
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in human ES colonies is an excellent tool to study undifferentiated stem cell substates (Tonge 
et al., 2011).  
Even though SSEA3 is closely associated with the undifferentiated phenotype of human ES 
cells, it has also been shown that it is not necessary for human development. This antigen 
together with SSEA4 is expressed on red blood cells, however a small percentage of the 
human population have red cells that do not synthesise these globoseries antigens (Tippett 
et al., 1986). Nevertheless, the importance of SSEA3 in undifferentiated cells was highlighted 
in a comparative analysis of early passage diploid human ES cells and later passage, culture 
adapted variants (Enver et al., 2005) where it was suggested that undifferentiated human ES 
cells exist in two substates: SSEA3Positive and SSEA3Negative. It has recently been reported that 
undifferentiated ES cells can be separated into functionally discrete subpopulations based on 
their SSEA3 expression profile (SSEA3High, SSEA3Low, and SSEA3Negative) (Tonge et al., 2011). 
The findings gleaned from the study carried out by Enver and colleagues in 2005 established 
that in the early passage diploid cells, SSEA3Positive stem cell substate was speculated to be 
particularly unstable, hence very few undifferentiated SSEA3Negative stem cells could be 
detected by clonogenic assays. Nevertheless, the phenomenon of culture adaptation seemed 
to ‘trap’ the cells in the stem cell compartment making the clonogenic 
SSEA3Negative undifferentiated stem cells detectable in the variant later passage lines. The cells 
in the SSEA3Negative subpopulation of human ES cells is less stable and closer to committing to 
differentiate than cells found in the SSEA3Positive  substate (Enver et al., 2005). 
Based on these findings, the study by Tonge et al., in 2011 further suggested that cells with 
different properties with regard to differentiation potential exist in the pluripotent human ES 
cell compartment. The study examined the functional heterogeneity of ES cells by testing the 
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capacity of single cells to choose between a neural or non-neural fate in human ES and EC 
cells (Tonge et al., 2011). 
NTERA2 EC cells were used in the study described by Tonge and cols in 2011 to track and 
model the expression of SSEA3 in human pluripotent stem cells, further highlighting their 
impact on stem cell research. It was also noted that the cloning efficiency of human ES and 
EC cells is closely dependant on the expression of SSEA3, which further underlines the 
importance of this sensitive marker in assessing the health of pluripotent stem cell cultures 
(Tonge et al., 2011). 
Thanks to studies like the ones mentioned above, it has been proposed that the stem cell 
compartment exists as a continuum of substates where cells oscillate in their propensity to 
reaching a differentiation threshold (Tonge et al., 2011). This, in turn, encourages the further 
study and characterisation of these substates by trying to identify novel antigens that define 
specific subsets of cells within the stem cell compartment. 
 
1.3.2 Novel cell surface antigens 
It is important to stress the need for a novel set of surface markers to identify subsets of cells. 
This is because as mentioned earlier, many of the strategies that are intended to be used in 
the clinic rely heavily on the premise of being able to isolate specific subpopulations of stem 
cells from the larger population in which they exist.  
Being able to identify and define new stem cell substates would make the application of 
therapeutic strategies more readily available by providing scientists with a greater insight into 
the intricate mechanisms that govern cell fate choice. 
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Many studies have made use of commonly surface markers either alone or in combination to 
try and identify substates of cells. For example, human ES cells that exhibit ectodermal bias 
have been postulated to be identified by the use of the marker CD133 (King et al., 2009). 
Others have proposed to look for expression of CD24, podocalyxin and GCTM2 as markers of 
mesoderm progenitors (Lin et al., 2010). 
Currently, with all of the studies that have been performed in human ES and EC cells, it would 
seem narrowly minded to think that the markers that exist and that have been extensively 
used to date are enough to define the undifferentiated state of human pluripotent stem cells. 
Therefore, this issue has started to be addressed by trying to derive new antibodies that are 
capable of defining novel stem cell substates (Wright et al., 2011). 
Many features of the panel of antibodies described by Wright and collaborators in 2011 were 
studied and characterised. However, more experiments are needed in order to establish a 
more definitive outline of the abilities of these antibodies to identify new possible substates, 
which is in turn the basic question that this present study aims to address. A summary of the 
general properties of these novel antibodies is presented in table 1. 
Antibody Isotype Reactivity Summary 
    N2102Ep NTERA2 H7.S6   
AA11 IgM + + * glycolipid/ganglioside 
AG10 IgM + + + glycolipid/ganglioside 
BE12 IgM + * * 
non-sialated; non-
ceramide 
BF4 IgM + + + sialated; non-ceramide 
CC9 IgM + + + sialated; non-ceramide 
CH8 IgG + + + 
non-sialated; non-
ceramide 
DA9 IgM * + * sialated; non-ceramide 
EF12 IgM + + + glycolipid/ganglioside 
 
Table 1. General properties of novel set of antibodies. The reactivity of the antibodies in the three different 
cell lines is the one reported in this study. + symbol = High reacitivity. * symbol = Low reactivity 
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Chapter 2 
2 Materials and Methods 
2.1 Cell culture 
2.1.1 Culture of Human ES cells 
 
The Human embryonic stem cell line used in this study was a subline of H7, H7.S6 (Andrews, 
Matin, et al., 2005).  Cells were cultured in growth media consisting of, Knockout-DMEM (Life 
Technologies) supplemented with 20% knockout-serum replacement (KO-SR, Life 
Technologies) , 1X non-essential amino acids (Life Technologies), 1mM glutamine (Sigma-
Aldrich), 0.1mM β-Mercaptoethanol (Sigma-Aldrich) and 4ng/ml bFGF (Life Technologies).  
Cell were routinely passaged by treatment with collagenase type IV (Life Technologies) and 
scraping with sterile glass-beads (Sigma-Aldrich), transferred to fresh flasks containing seeded 
6 x 103 cells/cm2 mitomycin C-treated MF-1 mouse embryonic fibroblasts at a split ratio of 1:5 
every 5-7 days.   Cells were cultured at 37°C in humidified atmosphere of 5% CO2.   
 
2.1.2 Culture of Human EC cells 
Human embryonal carcinoma cells used in this study was NTERA2 clone D1 (Fogh & Trempe, 
1975; Andrews, et al., 1984) and N2102Ep (Andrews, Bronson et al., 1980; Andrews, et al., 
1982).  
Cells were grown using Dulbecco’s Modified Eagle’s Medium, containing 4500 mg glucose / 
litre, L-glutamine, NaHCO3, pyridoxine HCl, (DMEM, Life Technologies) supplemented with 
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10% by volume foetal calf serum (Gibco BRL) and 2mM L-glutamine (Sigma-Aldrich). Tissue 
culture flasks were incubated in a humidified atmosphere of 10% CO2 in air at 37°C. 
 
2.2 Gene expression analysis 
2.2.1 RNA Extraction 
Both human ES and EC cells were washed once with Dulbecco’s PBS (without Mg2+, 
Ca2+)(dPBS) and dissociated by treatment for 1 minute at 37°C with 1ml of trypsin (0.25% w/v 
in EDTA).  Cells were collected in FACS buffer (PBS + 5% FBS) to neutralise the trypsin and 
centrifuged for 3 minutes at 104g. The pellet was then re-suspended in 1ml of TRIzol reagent 
(Life Technologies) and left for 5 minutes at room temperature. 200µl of chloroform (Sigma-
Aldrich) per 1ml of Trizol was added and samples were vortexed. The samples were then 
centrifuged at 10,000g for 10 minutes at 4°C. 
The colourless upper aqueous phase was carefully transferred into a new 1.5ml Eppendorf 
tube and 500µl of Isopropanol (Sigma-Aldrich) per 1ml of TRIzol was added. The samples were 
incubated overnight at -20°C. The precipitate was centrifuged at 14,000g for 20 minutes at 
4°C. The pelleted RNA was then washed once with 1ml of 75% Ethanol and centrifuged at 
14,000g for 10 minutes. After this, the pellet was left to air-dry for 5-10 minutes and then re-
dissolved in RNAse free H2O.  
RNA concentration was measured by using a nanophotometer (Geneflow) by absorbance at 
260nm.  
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2.2.2 Synthesis of complementary DNA (cDNA) 
cDNA was synthesized from total purified RNA using Oligo dT(15-18) and random hexamers  
primers using the following recipe.  The following were added to a 500µl tube: 
- 1µg of purified total RNA 
- 1µl of oligo dT primer (1µg/µl) 
- 1µl hexaprimers (0.5µg/µl) 
- 9µl of DEPC-treated H2O 
To prime the RNA for reverse transcription primers were annealed by heating up the mixture 
for 5 minutes at 70°C. Then the following was added to the sample: 
- 4µl 5x RT buffer (Life Technologies) 
- 2µl of 0.1 M Dithiothreitol DTT (Life Technologies) 
- 1µl of 10mM dNTPs (Life Technologies) 
The samples were pre-incubated at 25°C for 5 minutes before 1µl of 200 units MMLV reverse 
transcriptase (Life Technologies) was added. The reverse transcription reaction was then 
carried out with the following specifications: 
25°C for 5 minutes; 42°C for 60 minutes; 70°C for 10 minutes; 4°C hold 
The completed reaction samples were then used directly for PCR or stored at -20°C. 
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2.2.3 Quantitative Polymerase Chain Reaction (QPCR) 
For analysis of gene expression levels a master mix containing QPCR 10ng of cDNA, AmpliTaq 
Gold DNA polymerase (Life Technologies), Uracil-DNA glycosylase (Life technologies) and 
dNTP’s (including dUTP) was made up using the following recipe. 
 
 
 
 
 
 
 
For each QPCR reaction, 1.5 µl of the following TaqMan Assay-on-demand primer pairs (Life 
technologies) was added to 28.5μl of amplification master mix. 
Gene Assay-on demand 
ACTB Hs01060665_g1 
POU5F1(OCT4) Hs03005111_g1 
GATA6 Hs00232018_m1 
SOX17 Hs00751752_s1 
Brachyury (T) Hs00610080_m1 
Amplification Master Mix  
Taqman Gene expression Master Mix  
(Life Technologies, cat no 4369016) 
125µl 
 
H2O 120µl 
cDNA 5µl 
Total 250 µl 
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MIXL1 Hs00430824_g1 
OTX2 Hs04332701_m1 
SOX1 Hs01057642_s1 
PAX6 Hs002240821_m1 
 
QPCR reactions were performed in in 96 well PCR amplification plates (Life Technologies) 
using an Applied Biosystems QuantStudioTM 12K Flex real-time PCR system (Life 
Technologies).  For each set of QPCR reactions an ACTB amplification that replaced cDNA with 
H2O was amplified as a negative control.  Each QPCR reaction was analysed in triplicate with 
the specific gene expression values normalized to the ACTB threshold cycle for each sample. 
 
2.3 Immunofluorescence 
2.3.1 In-situ Immunostaining 
Cells were cultured on 12 well plates for 5 days after seeding at clonogenic densities (200 cells 
per cm2) and medium removed. Cells were washed once with PBS and then fixed with 4% 
Paraformaldehyde (PFA) for 15 minutes at room temperature. PFA was washed with PBS and 
plates were then stored at 4°C or immediately subjected to antibody staining.  
Cells were dual-stained with SSEA3/OCT4 and were first incubated for 30 minutes in block 
solution (PBS + 5% FBS). Anti-SSEA3 (1:10) was then added for 1 hour and left at room 
temperature. Cells were then washed with PBS + 5%FBS (wash buffer) and incubated with the 
secondary antibody for 1 hour. After washing the cells again, triton detergent solution was 
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added for 1 hour and left at 4°C. Cells were washed and anti-OCT4 was added to the wells and 
left at 4°C overnight. 
After washing the cells, the secondary antibody was added together with Hoechst 33342 for 
nuclei staining. Plate were stored at 4°C before imaging with an InCell Analyser 1000 (GE 
Healthcare) and analysis by Developer Toolbox Software (GE Healthcare). 
 
2.3.2 Flow Cytometry/Fluorescence Activated Cell Sorting analysis 
Confluent T25 flasks of human ES and EC cells were treated with 1ml trypsin EDTA for 2 
minutes until in single cell suspension. Nine ml of wash buffer were added to the cell 
suspension to neutralise trypsin. The suspension was then transferred to a sterile 15ml tube 
and cells were counted and centrifuged at 800 rpm for 5 minutes. Supernatant was discarded 
and the pellet resuspended in wash buffer in a volume of 107 cells per ml. The cell suspension 
(200µl) was added to sterile FACS tubes and the primary antibody was diluted to a working 
volume of 1:10. The tubes were then placed on a shaker at 4°C for 30 minutes. After this, cells 
were centrifuged at 1200 rpm for 3 minutes. Supernatant was discarded and cells were 
washed 2 more times doing the same procedure. Secondary antibody was added at a working 
dilution of 1:100 and placed on shaker for 30 minutes. Cells were spun down and washed as 
before and the cells were resuspended in 1ml of wash buffer for each sample. Samples that 
were to be sorted using FACS were done so using a Dakocytomation MoFlo prior to being 
replated into 12 well plates at clonogenic density (1000 cells per well). Normal flow cytometry 
was performed with a Dakocytomation CyAN. 
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2.3.3 Quantitative Data Analysis 
For flow cytometry, the data was plotted on histograms showing FITC intensity on a 
logarithmic scale against cell number. The positive and negative populations of cells stained 
for a particular antibody were discriminated by isolating a region of the histogram using a P3X 
negative control as a cut-off point. 
In order to extract cell and colony information from in-situ stained samples collected by the 
In Cell Analyser 1000 high-content microscope system the Hoechst 33342 nuclei in each image 
were segmented using the Developer Toolbox software (GE Healthcare).  The segmented 
nuclei were used to (1) Directly to count the number of cells in a field (2) to mask an area 
within the antibody staining image channel that would allow unambiguous identification of 
the cells and measurement of the fluorescent intensity of the antigen being probed in each 
cell, (3) by expanding the area assigned to each nuclei the closely spaced nuclei found in 
colony merge together thus demarking the position of colonies within a field. 
Colonies could be identified and quantified both in terms of total cells contained within a 
colony, the fluorescent intensity associated with each cell within a colony and thus whether 
a cell was positive or negative and total area in µm2 associated with each colony. Data was 
then exported to an Excel spreadsheet divided by well (summarising information on the total 
number of cells and positive cells) or by colony. Scatter and histogram plots were then created 
using SPSS Statistics software by IBM. 
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Table of antibodies: 
Primary Antibody Reference Concentration 
P3X Kohler & Milstein, 1975 1:10 (flow cytometry) 
MC-480 (SSEA1) Solter & Knowles, 1978 1:10 (flow cytometry) 
MC-631 (SSEA3) Shevinsky, et al., 1982 1:10 (flow cytometry/in-situ) 
MC-813-70 (SSEA4) Kannagi, et al., 1983 1:10 (flow cytometry) 
TRA-1-60 Andrews, et al., 1984 1:10 (flow cytometry) 
TRA-1-81 Andrews, et al., 1984 1:10 (flow cytometry) 
TRA-1-85 Williams, et al., 1988 1:10 (flow cytometry) 
Novel antibodies (AA11; AG10; 
BE12; BF4; CC9; CH8; DA9; EF12) 
Wright, et al., 2011 1:10 (flow cytometry) 
OCT4 Cell Signaling Technology 1:100 (in situ) 
Secondary Antibody Supplier Concentration 
Anti-Rat IgM Dylight-594 Jackson Immunoresearch 1:100 
Anti-Rabbit IgG Dylight 488 Jackson Immunoresearch 1:100 
SSEA3/AF647 conjugate antibody Made in-house 1:100 
TRA-1-60/AF488 conjugate 
antibody 
Made in-house 1:100 
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2.3.4 Antibody Conjugation 
The antibody conjugation of SSEA3 and TRA-1-60 with an Alexa Fluor 488 (FITC) and Alexa 
Fluor 647 (Cy5) respectively was performed in-house. Four different fractions of purified 
primary antibodies were measured in a spectrophotometer and based on their concentration, 
one particular fraction was chosen for conjugation.  
Zeba desalt spin columns (Fisher Scientific) were first washed three times with Sodium 
Bicarbonate (NaHCO3) buffer. 5ml of antibody and 5ml of sodium bicarbonate buffer were 
added to separate columns and spun down at 2,500 rpm for 2 minutes. The buffer filtrate was 
discarded and the antibody transferred to the next column. After the centrifugation steps, 
the respective fluorochrome in DMSO was added to the concentrated antibody, wrapped in 
foil and placed on a shaker set to low rocking for 1 hour. Three further washes were done 
after this and the sample was filtered through a 0.2µm filter. 
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Chapter 3 
3 Characterisation of the ability of a novel set of antibodies to identify 
subsets of human EC and ES cells 
 
3.1 Introduction 
 
A considerable amount of research has been done on the expression patterns of surface 
antigens displayed by ES and EC cells over the years. The stage specific embryonic antigen-1 
(SSEA1) was detected on mouse EC cells and in the ICM of early embryos from a monoclonal 
antibody (MC480) from lymphocytes of a mouse immunized with F9 EC cells in 1978 (Solter 
and Knowles, 1978). This antigen was found to be down-regulated on differentiation (Solter 
et al., 1979). Soon after, Shevinsky and collaborators produced another monoclonal antibody 
(MC631) by immunizing rats with four-cell cleavage stage mouse embryos. The antigen, 
SSEA3, is absent from mouse EC and ES cells, however it is present in human EC and ES cells 
(Shevinsky et al., 1982) (Damjanov et al., 1982) (Andrews et al., 1982) (Thomson et al., 1998b) 
(Reubinoff et al., 2000) (Draper et al., 2002). The antibody MC813-70 was later produced by 
immunizing with human EC cells and this antibody recognized the antigen SSEA4 (Kannagi et 
al., 1983). These studies paved the way for later characterization of other molecules that have 
been used as markers, such as the proposition that CD133 is useful in identifying human ES 
cells with ectodermal bias (King et al., 2009).  
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A novel set of monoclonal antibodies that might provide a new way of identifying 
subpopulations of cells within the stem cell compartment was recently described (Wright et 
al., 2011).  These antibodies were produced after immunisation of mice with human EC cells 
(2102Ep) and human ES cells (Shef1). Eight antibodies in total were derived and they all 
recognise surface antigens. Seven of these antibodies showed developmental regulation and 
most of them appear to detect epitopes different from the ones recognized by the previously 
mentioned and widely used markers of human ES cells. They offer the capability of increasing 
the resolution of the stem cell state. In this project, these antibodies were further analysed 
in order to see whether they were capable of identifying subsets of cells with distinct 
properties. 
Although the long term aim of this project is to provide tools for identifying substates within 
the undifferentiated compartment of human ES cells, EC cells such as the pluripotent line, 
NTERA2 (Andrews et al., 1984b) present some features that make them easier to control and 
analyse.  For example, they can be grown without feeders in a simpler medium, with minimal 
spontaneous differentiation.  This allows easier production of standardised cultures of cells 
for sorting by FACS to provide sufficient cells from minor set populations for subsequent 
analysis.  In this study, we therefore used NTERA2 EC cells together with the culture adapted 
human ES cell line, H7.S6, which also grows well and was previously shown to trap cells in 
substates that are transitory and otherwise difficult to detect (Enver et al., 2005).  The novel 
set of antibodies described by Wright et al 2011 were compared with well-known markers of 
human ES cells (SSEA3, SSEA4, TRA-1-60 and TRA-1-81) for their ability to detect sets of cells 
with differential characteristics of self renewal, differentiation and gene expression.  
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3.2 Results 
 
3.2.1 Antibody Titration 
In order to have a better understanding of how this novel set of antibodies reacts in human 
EC and ES cell lines, basic Fluorescent Activated Cell Sorting analysis was carried out in 
N2102Ep cells along with a titration assay to ensure the optimal concentration for all of the 
antibodies used in the experiments. The first group of antibodies, the standard set, comprised 
MC480, MC631, MC813-70, TRA-1-60, TRA-1-81 and TRA-1-85. The second group is the panel 
described by Wright et al 2011  comprising AA11, AG10, BE12, BF4, CC9, CH8, DA9 and EF12 
(Figure 1). 
The histograms in figure 1 are representative of three separate analyses for each antibody to 
show their distribution in N2102Ep cells. The first antibody, SSEA1, has a unimodal and rather 
defined distribution. This antibody is absent in undifferentiated cultures and becomes 
positive upon differentiation of cells. SSEA3 showed a broader, bimodal distribution and this 
antibody is a good marker for the undifferentiated state of stem cells. Its expression gradually 
decreases upon differentiation. SSEA4, another marker of the undifferentiated cells 
presented broad distributions when used at higher concentrations, whereas at lower 
concentrations, its distribution became more compact which suggests a loss in its capacity to 
mark cells. The expression of TRA-1-60 was positive throughout the different dilutions, but its 
distribution shifted towards the negative side as it became less concentrated. TRA-1-81 is a 
glycoprotein which is expressed on the surface of human EC and ES cells, just like the others 
and the antibody recognises a carbohydrate epitope. Its expression hardly fluctuated in 
N2102Ep cells at different concentrations, although its distribution did become broader as its 
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concentration decreased. TRA-1-85 showed a sharply peaked distribution with just a slight 
shift to the left of the histogram in the least concentrated sample. 
Next, antibodies from the panel described by Wright and colleagues were titrated. The first 
antibody, AA11, displayed a clearly bimodal distribution where most of the cells were on the 
positive side of the spectrum. AG10 showed a unimodal distribution with a long tail extending 
towards the negative side of the histogram. BE12 had a more compact distribution pattern 
which shifted to the negative side as the concentration of the antibody decreased. BF4 and 
CC9 showed a similar shaped histogram with a slight shift towards the negative side as less 
antibody was used. CH8 did not show much variation in its expression pattern and its 
distribution was quite similar to that of TRA-1-85. Both antibodies recognise a protein-based 
antigen (Williams et al., 1988). DA9 was the only antibody that did not mark a great 
percentage of cells. It was only at high concentrations that the antibody had a positive 
presence which quickly dropped as the concentration of the antibody was lowered. Lastly, 
EF12 showed a wide distribution across the different concentrations used and marked mostly 
positive cells within the population. Based on the histograms and the titration assays, the 
subsequent experiments were all performed using the antibodies at a 1:10 dilution (Figure 1 
& 1A). Although some antibodies showed a slightly better response when used at different 
dilutions (e.g. BF4), the majority of the responses from the antibodies stayed in the 1:10 range 
(Figure 1.1).  
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Titration Assay in N2102Ep with Standard set of antibodies 
 
 
  
  
SSEA1 – 1:5 
 
4.02% 
 
SSEA1 – 1:10 
 
5.07% 
 
3.93% 
 
SSEA1 – 1:20 
 
SSEA1 – 1:40 
 
1.85% 
 
SSEA3 – 1:5 
 
87.53% 
 
SSEA4 – 1:5 
 
84.93% 
 
SSEA4 – 1:10 
 
87.07% 
 
SSEA4 – 1:40 
 
96.06% 
 
Figure 1 – FACS histogram profiles from titration assays in N2102Ep with Standard antibodies. The 
titration assays were performed using different dilutions of antibody to determine the concentration 
to be used in subsequent experiments. Continued on page 29. 
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TRA-1-60 – 
 
95.78% 
TRA-1-60 – 
0 
93.14
% 
TRA-1-60 – 
1 20 
89.26
% 
TRA-1-60 – 
0 
74.38
% 
TRA-1-81 – 
 
98.83
% 
TRA-1-81 – 
1 10 
97.47
% 
TRA-1-81 – 
20 
96.16% 
TRA-1-81 – 
0 
91.66
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TRA-1-85 – 
 
98.99
% 
TRA-1-85 – 
1 10 
99.46
% 
TRA-1-85 – 
20 
99.09
% 
TRA-1-85 – 
0 
98.66
% 
Figure 1 – FACS histogram profiles from titration assays in N2102Ep with Standard antibodies. The 
titration assays were performed using different dilutions of antibody to determine the concentration 
to be used in subsequent experiments. 
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Titration curves for standard and novel set of antibodies in N2102Ep cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1a – Titration assay curves. The median fluorescent intensity was plotted against different 
dilutions for each antibody of the standard set of antigens and the novel set.  
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Titration assay in N2102Ep cells with novel set of antibodies. 
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AA11 – 1:10 
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AA11 – 1:40 
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AG10 – 1:5 
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BE12 – 1:5 
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74.70% 
 
CC9 – 1:10 
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DA9 – 1:5 
DA9 – 1:10 
31.06% 
26.66% 
DA9 – 1:20 
10.16% 
DA9 – 1:40 
5.60% 
EF12 – 1:5 
89.04% 
EF12 – 1:10 
93.43% 
EF12 – 1:20 
91.52% 
EF12 – 1:40 
88.46% 
Figure 1.1 FACS histogram profiles from titration assays in N2102Ep cells with the novel set of 
antibodies. The titration assays were performed using different dilutions (1:5; 1:10; 1:20; 1:40) of 
antibody to determine the concentration to be used in subsequent experiments. 
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3.2.2 Antigen Expression Patterns in human Pluripotent Stem Cells, NTERA2 and H7.S6 
To assess whether the new antibodies may identify substates of human ES cells distinct from 
those detected by the standard set of commonly used antibodies, we compared the 
fluorescence flow cytometry profiles obtained following their binding to 2102Ep nullipotent 
EC cells, NTERA2 pluripotent EC cells and H7.S6 human ES cells (Figures 2 and 3; Table 1).  
Three biological replicates were carried out for each antibody and cell line, generally giving 
comparable results.  A representative histogram for each is shown in Figures 2 and 3; the data 
for all replicates are summarised in Table 1.  
The first difference found on these figures is that the expression of SSEA1 is slightly higher in 
ES cells than in EC cells. The population in this fraction seems to be rather defined with a 
unimodal distribution in the three cell lines. SSEA3 and SSEA4 showed good positive reactivity 
in the three cell lines, especially in NTERA2. The distributions for the SSEA3 fraction are bi-
modal in NTERA2 and H7.S6 but unimodal in N2102Ep. Likewise, SSEA4 showed a more 
defined unimodal distribution in NTERA2 and H7.S6. 
The expression of TRA-1-60; TRA-1-81 and TRA-1-85 was positive in all cells and they showed 
unimodal distributions with the exception of H7.S6 in which TRA-1-60 and TRA-1-81 displayed 
broad bi-modal distributions. The expression profile of TRA-1-85 seems very similar to that of 
CH8 possibly due to their relationship in both recognising protein antigens on the cell surface 
(Wright et al., 2011) (Williams et al., 1988). 
Next, the expression profile patterns of the novel panel of antibodies were analysed. The first 
antibody, AA11, reacted in both EC cell lines. However, AA11 was mostly negative in ES cells 
where only 24% of the cells showed a positive expression. AG10 was positive in the three cell 
lines and its expression was quite similar between H7.S6 and NTERA2, where the distribution 
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was clearly bimodal, whereas in N2102Ep cells AG10 exhibited a unimodal distribution. BE12 
was only present in N2102Ep cells with 85% of them being positive for this antibody. This 
antibody, however, showed very low expression in ES cells and in NTERA2 cells. BF4 displayed 
a very wide distribution in all three cell lines. CC9 was also present in the three cell lines and 
its distribution was rather different across all three. In ES cells, its distribution was bimodal 
whereas in NTERA2 cells the distribution was more unimodal.  Although still unimodal in 
N2102Ep cells, the distribution of CC9 reactivity was not as defined, but was spread more 
across the spectrum of positive and negative cells. CH8 had a single distinctive sharp peak 
that resembled that of TRA-1-85. Of all the eight Axordia Antibodies, DA9 was the only one 
that showed very low reactivity in N2102Ep cells, less than 30% of them were positive. 
However, NTERA2 cells showed a good response to this antibody showing a bimodal 
distribution. In ES cells the expression of DA9 was practically non-existent. Finally, EF12, was 
present in the three cell lines and its distribution was quite wide and bimodal, although a little 
less defined in N2102Ep cells. By looking at these FACS expression profiles of the antibodies 
in three cell lines it is evident that there is heterogeneity within the stem cell population. 
Therefore, the next step was to have a closer look at how these antibodies might help dissect 
subpopulations of cells by performing further experiments such as clonogenic assays and 
looking at the varying influence that the antibodies might have on the expression of markers 
characteristic of the undifferentiated state, such as OCT4 and SSEA3. 
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99.86%
SSEA3
80.10%
SSEA1
9.03%
TRA-1-60
97.54%
TRA-1-81
90.50%
TRA-1-85
99.94%
SSEA1
34.46%
SSEA3
60.50%
SSEA4
98.13%
TRA-1-60
90.42%
TRA-1-81
90.54%
TRA-1-85
98.31%
 N2102Ep 
NTERA2 
H7.S6 
Figure 2. Representative flow cytometric histograms for standard antibodies. FACS histogram profiles 
showing a representative expression for each antibody of the standard set in N2102Ep, NTERA2 and H7.S6. 
Filled histogram = Antibody staining. Blank histogram = P3X negative control 
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Figure 3. Representative flow cytometric histograms for novel antibodies. FACS histogram profiles showing 
a representative expression for each antibody of the standard set in N2102Ep, NTERA2 and H7.S6. Filled 
histogram = Antibody staining. Blank histogram = P3X negative control 
N2102Ep 
NTERA2 
H7.S6 
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Antibody
SSEA-1 3.29 2.85 3.06 4.73 5.27 8.73 7.03 1.85 9.73
SSEA-3 209.69 126.46 123.36 202.25 195.07 279.94 44.37 24.01 37.04
SSEA-4 131.11 168.83 273.72 464.16 447.69 449.44 556.03 481.23 432.15
TRA-1-60 202.25 101.82 163.67 481.23 464.16 317.65 416.49 666.08 498.21
TRA-1-81 323.45 225.39 242.28 51.26 49.44 43.35 233.68 827.27 889.24
TRA-1-85 921.95 955.86 890.63 666.08 680.6 598.93 821.95 464.16 135.94
AA11 16.73 22.34 21.54 13.47 12.99 9.12 15.01 6.31 19.33
AG10 447.69 458.96 521.36 431.81 416.49 432.23 170.95 162.84 536.31
BE12 105.57 96.39 66.01 5.08 5.27 3.81 4.56 5.27 1.66
BF4 23.16 42.79 19.33 447.69 431.81 444.37 55.1 88.15 53.5
CC9 188.15 105.57 118.46 195.07 181.48 105.57 33.23 61.82 55.1
CH8 431.81 403.52 413.25 769.62 762.7 635.94 195.07 189.24 270
DA9 5.66 5.87 3.67 46 56 77 4.9 2.65 3.06
EF12 202.25 576.48 517.28 242.28 233.68 215.98 185 131.11 279.11
Median Flourescent Intensity
N2102Ep
Median Flourescent Intensity Median Flourescent Intensity
NTERA2 H7.S6 
Antibody Percentage Positive Cells
SSEA-1 3.29 2.85 3.06 9.03 22.5 29.13 33.53 28.48 16.8
SSEA-3 87.53 83.01 77.97 80.1 79.62 87.62 74.18 62.02 70.73
SSEA-4 84.93 87.07 95.68 99.86 99.61 86.9 98.22 92.46 93.14
TRA-1-60 95.78 93.14 89.26 97.54 97.24 97.3 91.59 85.52 90.18
TRA-1-81 98.83 97.47 96.16 90.5 90 91.7 91.62 86.09 92.94
TRA-1-85 98.99 99.46 99.09 99.94 99.72 99.98 98.56 96.84 96.01
AA11 55.15 60.48 59.46 52 51.28 34.06 56.35 37.7 62.88
AG10 94.46 95.58 94.87 90.26 90.07 88.7 82.72 87.31 82.14
BE12 91.15 85.06 70.46 7.91 8.37 7.54 22.5 18.46 8.68
BF4 63.62 74.7 59.47 92.64 92.38 90.57 76.56 73.06 77.11
CC9 94.63 91.34 78.18 92.64 92 95.84 83.34 84.26 83.55
CH8 99.78 99.83 99.35 99.78 99.59 99.29 98.58 98.09 93.32
DA9 31.06 26.66 10.16 78 77 62.85 4.51 17.32 5.55
EF12 89.04 93.43 91.52 88.39 87.92 92.59 83.86 84.93 79.83
N2102Ep
Percentage Positive Cells Percentage Positive Cells
NTERA2 H7.S6 
Table 2. Median Flourescent Intensity and Percentage of positive cells. Replicate data for the three cell lines 
(N2102Ep, NTERA2 and H7.S6). 
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3.2.3 Clonogenic Assays in EC cells (NTERA2) 
To assess whether cells expressing or lacking the new antigens exhibited differentiated 
functional properties, cells were isolated by FACS according to their level of antigen 
expression and plated out at clonal densities. The resulting colonies were then assessed by a 
high content colony screening. 
Each sorted population (positive and negative) was analysed for different aspects of colony 
growth. First, the cloning efficiency of each fraction was analysed. Then, I looked at the 
percentages of positive SSEA3 and OCT4 cells per colony. Next, the size of colonies was 
assessed both in terms of number of cells per colony and the physical area occupied by each 
colony. This is represented by scatter plots of these parameters against the percentage of 
OCT4 and SSEA3 positive cells per colony. And finally, the relationship between the 
percentage of positive SSEA3 and OCT4 cells per colony was also determined with a scatter 
plot. Both positive and negative fractions of each antibody were taken into account in these 
graphs. 
The first antibody to be assessed for all these features was AA11. Cells negative for AA11 had 
good cloning efficiency, followed by its positive counterpart (Figure 4A). However, this high 
cloning efficiency could simply be due to the cells being analysed on different days. However, 
because of a lack of time, no biological replicates were obtained for this antibody. 
The percentage of SSEA3 and OCT4 positive cells per colony was low and there was no 
considerable difference between the positive and the negative fractions (Figure 4.1A). The 
size of colonies expressing either SSEA3 or OCT4 positive cells per colony was relatively the 
same, where the smallest colonies consisted of four cells and the largest ones had just over 
four thousand cells in the positive fraction (Figure 4.1B). In terms of area occupied by the 
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colonies, again their size was relatively comparable between colonies positive for SSEA3 and 
colonies positive for OCT4 (Figure 4.1C). The correlation between OCT4 positive cells per 
colony with SSEA3 positive cells per colony was low in general, although there were a few 
instances where the cells that grew back where positive for both OCT4 and SSEA3 (Figure 
4.1D). The low expression of both SSEA3 and OCT4 in these colonies could mean that the cells 
come from differentiated cells. 
The next antibody, AG10, had a cloning efficiency of less than 10% for both fractions (Figure 
4A) and the positive fraction had a better cloning efficiency than its negative counterpart. 
AG10, showed a notorious difference with respect to AA11 between the percentage of 
positive SSEA3 and OCT4 cells per colony amongst fractions (Figure 4.2A). The positive 
fraction of AG10 had a greater number of cells that were positive for both SSEA3 and OCT4 
than the negative fraction (Figure 4.2B). The colonies that reformed from both fractions were 
small overall in terms of surface area when measuring either SSEA3 or OCT4. There were also 
similar numbers of SSEA3 positive and negative cells, likewise OCT4 positive and negative cells 
(Figure 4.2C). The positive fraction of AG10 showed a slight advantage in terms of its cells 
being positive for both SSEA3 and OCT4 and in general, less than 80% of the two fractions 
were positive for both SSEA3 and OCT4 (Figure 4.2D). AG10 positive colonies are likely to 
come from undifferentiated cells since they had high levels of expression of both SSEA3 and 
OCT4. 
The clonogenicity of the BF4 sorted populations was less than 10% and the positive fraction 
had better cloning efficiency than the negative fraction (Figure 4A). The BF4 positive fraction 
showed a slightly higher number of cells for OCT4 than the negative fraction. However, the 
percentage of SSEA3 positive cells per colony was very low in both fractions (Figure 4.3A). The 
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size of colonies was small in terms of surface area for both fractions in general when looking 
at the percentage of OCT4 positive cells per colony. The number of cells per colony for OCT4 
positive cells was low as well (Figure 4.3B). When looking at the percentage of SSEA3 positive 
cells per colony, the size of the few SSEA3 positive cells was also small both in terms of number 
of cells per colony and the area of the colony (Figure 4.3C). There was little correlation 
between OCT4 and SSEA3 positive cells per colony in amongst fractions of BF4 (Figure 4.3D). 
BF4 positive colonies are also likely to come from undifferentiated cells since they exhibited 
high levels of OCT4. 
The cloning efficiency of the CC9 sorted populations was lower than 5% and there was little 
difference between the positive and the negative fractions (Figure 4A). CC9 showed some 
significant difference across fractions of sorted cells, just like AG10. The number of cells that 
were positive for SSEA3 after reseeding was higher in the positive fraction compared to the 
negative counterpart. However, for OCT4 there was not much of a difference between the 
fractions (Figure 4.4A). When measuring the size of the colonies by looking at the percentage 
of OCT4 positive cells per colony against the number of cells per colony and the surface area 
of the colony, the positive fraction had a higher presence in the scatter plots compared to the 
negative fraction. The size of colonies was consistent with the size of the other antibodies and 
when all the cells in the colony expressed OCT4 their size ranged from 4 to 30 cells per colony 
for the positive fraction (Figure 4.4B). There was no great difference in the size of colonies 
when looking at the percentage of SSEA3 positive cells per colony (Figure 4.4C). There was no 
strong correlation between the positive and negative fractions for the percentages of OCT4 
and SSEA3 positive cells per colony (Figure 4.4D). In the case of CC9 positive colonies, the fact 
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that they showed high levels of SSEA3 suggested that these colonies formed from 
undifferentiated cells. 
CH8 positive cells cloned better than the negative fraction (Figure 4A). The positive fraction 
of CH8 had more cells that expressed OCT4 after seeding. The percentage of SSEA3 positive 
cells per colony however was very low in both fractions (Figure 4.5A). This may be indicative 
that the positive colonies formed from undifferentiated cells. More than a hundred cells per 
colony were positive for OCT4 and the size of the colonies overall in terms of number of cells 
per colony consisted of 60 or less cells. The area occupied by OCT4 positive colonies was 
consistent with the size for the previous antibodies (200000µm2) (Figure 4.5B). The size of the 
colonies positive for SSEA3 was very similar to that of OCT4 (Figure 4.5C). The positive fraction 
of CH8 had a good correlation between cells positive for SSEA3 and OCT4 and some of the 
negative CH8 cells also had a good correlation of OCT4 and SSEA3 positive cells (Figure 4.5D). 
The DA9 negative population had a slightly better cloning efficiency than the positive fraction 
(Figure 4A). DA9 did not show much difference between fractions in terms of percentage of 
positive SSEA3 cells per colony or OCT4 positive cells (Figure 4.6A) but the high expression of 
OCT4 in positive colonies suggests they come from undifferentiated cells. The number of cells 
positive for OCT4 was slightly higher than for SSEA3. The size of colonies that were positive 
for OCT4 was very similar to the other antibodies and there was practically no difference in 
size between those colonies with no OCT4 positive cells at all and colonies with 100% OCT4 
positive cells. They had a size no bigger than 40 cells per colony overall. Their surface area 
was also quite similar and consistent with the other antibodies (Figure 4.6B). The size of SSEA3 
positive colonies showed a difference between those that had few or no SSEA3 positive cells 
at all and those with a hundred percent of their cells positive for SSEA3. The latter were 
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slightly bigger with a few colonies having more than 50 cells per colony. Colonies negative for 
SSEA3 had less than 20 cells per colony. The area occupied by SSEA3 positive colonies had a 
maximum value of 400000µm2 but their size overall was consistent with the other antibodies 
(Figure 4.6C). There was also a high correlation of OCT4 and SSEA3 positive cells per colony 
(Figure 4.6D). 
Lastly, EF12 positive cells cloned better than the negative population (Figure 4A) and the EF12 
sorted fractions showed a difference between them in the percentage of SSEA3 positive cells 
per colony. The positive fraction yielded more cells with a high percentage of SSEA3 
expression and both fractions were positive for OCT4 (Figure 4.7A). The size of colonies 
positive for OCT4 was consistent with the rest of the antibodies. There was not much 
difference in size between cells positive for SSEA3 and the negatives. The area of the colonies 
was also consistent with the rest of the antibodies (Figures 4.7 B-C). There was a greater 
correlation between OCT4 and SSEA3 positive cells in the positive fraction of EF12 compared 
to the EF12 negative fraction (Figure 4.7 D). Both fractions (positive and negative) had high 
expression of OCT4 which suggests that the colonies grew from undifferentiated cells. 
SSEA3 was used to compare the response of the novel antibodies with a more common 
marker. The cloning efficiency of the sorted populations of SSEA3 was not far off from that of 
the rest of the antibodies (Figure 4 A). Overall, it was very similar in terms of percentage of 
cells that grew back after seeding and the positive sorted fraction of SSEA3 cloned slightly 
better than the negative population. The positive fraction of SSEA3 showed a slight advantage 
in terms of percentage of SSEA3 positive cells per colony compared to the negative 
population. The percentage of OCT4 positive cells per colony between sorted fractions was 
very similar (Figure 4.8 A). In terms of size, the colonies with 100% of OCT4 positive cells in 
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both sorted fractions had between 4 and 50 cells per colony and the area occupied by them 
was around 100000µm2. The colonies positive for SSEA3 were also very similar in this aspect 
of size (Figure 4.8 B-C). The colonies with 100% SSEA3 and OCT4 positive cells were not many 
but there was more correlation with increasing percentages (Figure 4.8 D).   
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Figure 4. Cloning efficiency of sorted populations in EC (A) and ES (B) cells. Grey bars represent 
biological replicates. All other samples were from single biological samples. 
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Figure 4.1 A) Frequency histograms for the percentage of SSEA3 and OCT4 positive cells per colony. B, C) 
Size of colonies - in terms of number of cells per colony and area for OCT4 and SSEA3 positive cells. D) 
Percentage of OCT4 positive cells per colony vs percentage of SSEA3 positive cells per colony. E) qPCR – 
Positive fraction (Blue), negative fraction (Orange) and unsorted culture (Green). Genes of endoderm 
(GATA6, SOX17), mesoderm (T, MIXL1) and ectoderm (OTX2, PAX6). 
NTERA2 
AA11 
A 
B 
C 
D E 
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Figure 4.2 A) Frequency histograms for the percentage of SSEA3 and OCT4 positive cells per colony. B, C) 
Size of colonies - in terms of number of cells per colony and area for OCT4 and SSEA3 positive cells. D) 
Percentage of OCT4 positive cells per colony vs percentage of SSEA3 positive cells per colony. E) qPCR – 
Positive fraction (Blue), negative fraction (Orange) and unsorted culture (Green). Genes of endoderm 
(GATA6, SOX17), mesoderm (T, MIXL1) and ectoderm (OTX2, PAX6). 
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Figure 4.3 A) Frequency histograms for the percentage of SSEA3 and OCT4 positive cells per colony. B, C) 
Size of colonies - in terms of number of cells per colony and area for OCT4 and SSEA3 positive cells. D) 
Percentage of OCT4 positive cells per colony vs percentage of SSEA3 positive cells per colony. E) qPCR – 
Positive fraction (Blue), negative fraction (Orange) and unsorted culture (Green). Genes of endoderm 
(GATA6, SOX17), mesoderm (T, MIXL1) and ectoderm (OTX2, PAX6). 
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Figure 4.4 A) Frequency histograms for the percentage of SSEA3 and OCT4 positive cells per colony. B, C) 
Size of colonies - in terms of number of cells per colony and area for OCT4 and SSEA3 positive cells. D) 
Percentage of OCT4 positive cells per colony vs percentage of SSEA3 positive cells per colony. E) qPCR – 
Positive fraction (Blue), negative fraction (Orange) and unsorted culture (Green). Genes of endoderm 
(GATA6, SOX17), mesoderm (T, MIXL1) and ectoderm (OTX2, PAX6). 
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Figure 4.5 A) Frequency histograms for the percentage of SSEA3 and OCT4 positive cells per colony. B, C) 
Size of colonies - in terms of number of cells per colony and area for OCT4 and SSEA3 positive cells. D) 
Percentage of OCT4 positive cells per colony vs percentage of SSEA3 positive cells per colony. E) qPCR – 
Positive fraction (Blue), negative fraction (Orange) and unsorted culture (Green). Genes of endoderm 
(GATA6, SOX17), mesoderm (T, MIXL1) and ectoderm (OTX2, PAX6). 
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Figure 4.6 A) Frequency histograms for the percentage of SSEA3 and OCT4 positive cells per colony. B, C) 
Size of colonies - in terms of number of cells per colony and area for OCT4 and SSEA3 positive cells. D) 
Percentage of OCT4 positive cells per colony vs percentage of SSEA3 positive cells per colony.  
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Figure 4.7 A) Frequency histograms for the percentage of SSEA3 and OCT4 positive cells per colony. B, C) 
Size of colonies - in terms of number of cells per colony and area for OCT4 and SSEA3 positive cells. D) 
Percentage of OCT4 positive cells per colony vs percentage of SSEA3 positive cells per colony. E) qPCR – 
Positive fraction (Blue), negative fraction (Orange) and unsorted culture (Green). Genes of endoderm 
(GATA6, SOX17), mesoderm (T, MIXL1) and ectoderm (OTX2, PAX6). 
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Figure 4.8 A) Frequency histograms for the percentage of SSEA3 and OCT4 positive cells per colony. B, C) 
Size of colonies - in terms of number of cells per colony and area for OCT4 and SSEA3 positive cells. D) 
Percentage of OCT4 positive cells per colony vs percentage of SSEA3 positive cells per colony. E) qPCR – 
Positive fraction (Blue), negative fraction (Orange) and unsorted culture (Green). Genes of endoderm 
(GATA6, SOX17), mesoderm (T, MIXL1) and ectoderm (OTX2, PAX6). 
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3.2.4 Clonogenic Assays in ES cells (H7.S6) 
The cloning efficiency for ES cells was lower overall compared to that of EC cells. AA11 showed 
less than 2% cloning efficiency for both positive and negative fractions (Figure 4B). AA11 did 
not show much difference between fractions in the expression for SSEA3 and OCT4 in ES cells 
(Figure 5A). The size of the colonies was smaller than in EC cells both in terms of number of 
cells per colony and in surface area when looking at the percentage of OCT4 positive cells 
(Figure 5B). The size of colonies when looking at the expression of SSEA3 was also small and 
comparable to that of OCT4 (Figure 5C). There was low correlation between OCT4 and SSEA3 
positive cells as well (Figure 5D). 
The positive fraction of AG10 had a slightly better cloning efficiency than the negative fraction 
but both were lower than 2% (Figure 4B). AG10 fractions were similar in their expression of 
SSEA3 and OCT4 (Figure 5.1A). Neither fraction displayed an advantage over the other when 
looking at the percentage of both SSEA3 and OCT4. The size of colonies with OCT4 positive 
cells was small overall, although there were some colonies which were at least 50% positive 
for OCT4 with as many as 600 cells in the negative fraction of AG10. The largest colony of 
AG10 positive cells that expressed OCT4 (~40%) had about 450 cells. The area of the few OCT4 
positive colonies was less than 100000µm2 (Figure 5.1B). The size of SSEA3 positive colonies 
was very similar to the OCT4 population. Very few cells that were positive for SSEA3 were also 
positive for OCT4, only the positive fraction of AG10 showed some correlation in this respect 
(Figures 5.1 C-D). 
BE12 showed better cloning efficiency in the negative fraction compared to the positive 
population (Figure 4B). The negative fraction of BE12 displayed an increased number of cells 
expressing SSEA3 than the positive fraction. The positive fraction only had up to 70% positive 
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expression of SSEA3 whereas the negative fraction did have expression of 100% of SSEA3 in 
some cells. There was little difference in OCT4 expression between fractions but overall, the 
negative fraction had slightly more positive OCT4 cells (Figure 5.2A). The size of colonies in 
which there were some positive OCT4 cells was small for both fractions, these colonies 
consisted of less than 40 cells. As the percentage of OCT4 positive cells in the colonies 
decreased, their size increased. However, this was more noticeable in the negative fraction. 
The biggest colony, in terms of number of cells per colony, consisted of 250 cells in the 
negative fraction and only around 30% of those cells in the colony were positive for OCT4. 
The size of SSEA3 positive colonies was very similar and the area occupied by the colonies was 
also relatively the same in OCT4 and SSEA3 positive colonies of both fractions (Figure 5.2 B-
C). Only a few colonies of the negative BE12 fraction with 100% of SSEA3 expression were also 
100% positive for OCT4. In general, there was little correlation regarding this feature of the 
colonies (Figure 5.2D). 
BF4 showed a big increase in cloning efficiency in one of the replicates in both fractions. The 
positive fraction reported more than 6% efficiency whereas the negative fraction had an 
efficiency of 3.68% (Figure 4B). The cells from the BF4 fractions did not have a marked 
expression of SSEA3 after re-seeding and there was only a small difference in the expression 
of OCT4 (Figure 5.3A). The size of colonies was comparable between colonies with some 
expression of OCT4 and SSEA3. Overall, their size did not reach beyond 50 cells per colony. 
The largest colonies had 120 cells and the expression of OCT4 and SSEA3 was around 50% and 
they were found in the negative fraction of BF4. The area of the colonies was very similar as 
well (Figure 5.3 B-C). Only the positive fraction of BF4 showed a complete correlation between 
SSEA3 and OCT4 positive cells (Figure 5.3 D).  
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CC9 had a fairly similar cloning efficiency between replicates and the positive fraction cloned 
better than the negative fraction (Figure 4B). The sorted populations of CC9 showed some 
difference in the expression of SSEA3 positive cells per colony. The positive fraction had a 
higher number of cells with a high percentage of SSEA3 expression compared to the negative 
fraction. Also, there was a difference in the expression of OCT4 between the positive and the 
negative fraction (Figure 5.4 A). The size of the colonies with a high percentage of OCT4 and 
SSEA3 in terms of number of cells per colony was similar and the positive fraction displayed 
the largest colonies with a size of nearly 800 cells per colony, although their expression was 
very low for OCT4 but very high for SSEA3. In terms of surface area, there was a similarity 
between OCT4 and SSEA3 positive colonies. The positive fraction of CC9 occupied most of the 
spectrum in the plot. The largest colonies occupied an area of roughly 500000µm2 and they 
belonged to the CC9 positive fraction (Figure 5.4 B-C). There was slightly more correlation 
when looking at the relationship between OCT4 and SSEA3 positive cells per colony and it was 
only the positive fraction that had 100% of its cells in a colony expressing OCT4 and SSEA3 
(Figure 5.4 D). 
There was a clear difference in the cloning efficiency of the CH8 sorted fractions, with the 
positive population having a higher percentage of cloning than the negative fraction (Figure 
4B). The expression of SSEA3 in the CH8 positive fraction was also higher than in the negative 
population. However, the expression of OCT4 was practically the same between fractions 
(Figure 5.5 A). The size of CH8 positive colonies that expressed OCT4 was small in terms of 
number of cells per colony, although there was an instance in which a colony with around 
90% of OCT4 positive cells had more than 300 cells. The area of the majority of these colonies 
was less than 100000µm2. The colonies that had SSEA3 expressing cells were somewhat larger 
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overall both in terms of number of cells and surface area (Figure 5.5 B-C). There was some 
correlation in the expression of both OCT4 and SSEA3 (Figure 5.5D). 
The EF12 positive fraction had a high cloning efficiency compared to the rest of the antibodies, 
whereas the negative population had a low percentage of clones (Figure 4B). The positive 
fraction of EF12 also displayed greater expression of both SSEA3 and OCT4 than the negative 
fraction (Figure 5.6A). The size of colonies from both fractions with OCT4 positive cells was 
very similar. The majority of the colonies did not surpass 200 cells per colony. The biggest 
colonies were found in the positive fraction with as much as 800 cells per colony. The surface 
area of the colonies was also similar between fractions. Colonies with SSEA3 positive cells had 
a similar size to those that only expressed OCT4 both in terms of number of cells per colony 
and surface area. Again, the positive fraction presented bigger colonies than the negative 
fraction (Figure 5.6 B-C). There was a high correlation of SSEA3 and OCT4 positive cells for the 
positive fraction, whilst the negative population had lower levels of this feature (Figure 5.6D). 
The cloning efficiency of both sorted populations for SSEA3 was the same and overall it was 
very similar when compared to the rest of the novel antibodies (Figure 4 B). The percentage 
of SSEA3 positive cells per colony was very similar across the sorted fractions, although the 
positive fraction had two times more number of colonies containing 100% SSEA3 positive cells 
than the negative population. In the case of OCT4 positive cells per colony, the negative 
fraction showed just a little more number of colonies with 100% OCT4 positive cells than the 
positive population (Figure 5.7 A). The colonies with 100% OCT4 positive cells had less than 
fifty cells and accordingly, their surface area was also small. The biggest colony with a high 
percentage of OCT4 positive cells (> 90%) was found in the positive fraction of SSEA3 and 
consisted of almost 500 cells, with an area of nearly 600000µm2. The colonies positive for 
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SSEA3 in both fractions were also small, similar to those with OCT4 positive cells (Figure 5.7 
B-C).  There was a high correlation of colonies with high percentages of SSEA3 and OCT4 
positive cells for both sorted fractions (Figure 5.7 D). 
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Figure 5 A) Frequency histograms for the percentage of SSEA3 and OCT4 positive cells per colony. B, C) Size 
of colonies - in terms of number of cells per colony and area for OCT4 and SSEA3 positive cells. D) Percentage 
of OCT4 positive cells per colony vs percentage of SSEA3 positive cells per colony. E) qPCR – Positive 
fraction (Blue), negative fraction (Orange) and unsorted culture (Green). Genes of endoderm (GATA6, 
SOX17), mesoderm (T, MIXL1) and ectoderm (SOX1, PAX6). 
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Figure 5.1 A) Frequency histograms for the percentage of SSEA3 and OCT4 positive cells per colony. B, C) 
Size of colonies - in terms of number of cells per colony and area for OCT4 and SSEA3 positive cells. D) 
Percentage of OCT4 positive cells per colony vs percentage of SSEA3 positive cells per colony. E) qPCR – 
Positive fraction (Blue), negative fraction (Orange) and unsorted culture (Green). Genes of endoderm 
(GATA6, SOX17), mesoderm (T, MIXL1) and ectoderm (OTX2, PAX6). 
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Figure 5.2 A) Frequency histograms for the percentage of SSEA3 and OCT4 positive cells per colony. B, C) 
Size of colonies - in terms of number of cells per colony and area for OCT4 and SSEA3 positive cells. D) 
Percentage of OCT4 positive cells per colony vs percentage of SSEA3 positive cells per colony. E) qPCR – 
Positive fraction (Blue), negative fraction (Orange) and unsorted culture (Green). Genes of endoderm 
(GATA6, SOX17), mesoderm (T, MIXL1) and ectoderm (OTX2, PAX6). 
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Figure 5.3 A) Frequency histograms for the percentage of SSEA3 and OCT4 positive cells per colony. B, C) 
Size of colonies - in terms of number of cells per colony and area for OCT4 and SSEA3 positive cells. D) 
Percentage of OCT4 positive cells per colony vs percentage of SSEA3 positive cells per colony. E) qPCR – 
Positive fraction (Blue), negative fraction (Orange) and unsorted culture (Green). Genes of endoderm 
(GATA6, SOX17), mesoderm (T, MIXL1) and ectoderm (OTX2, PAX6). 
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Figure 5.4 A) Frequency histograms for the percentage of SSEA3 and OCT4 positive cells per colony. B, C) 
Size of colonies - in terms of number of cells per colony and area for OCT4 and SSEA3 positive cells. D) 
Percentage of OCT4 positive cells per colony vs percentage of SSEA3 positive cells per colony. E) qPCR – 
Positive fraction (Blue), negative fraction (Orange) and unsorted culture (Green). Genes of endoderm 
(GATA6, SOX17), mesoderm (T, MIXL1) and ectoderm (OTX2, PAX6). 
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Figure 5.5 A) Frequency histograms for the percentage of SSEA3 and OCT4 positive cells per colony. B, C) 
Size of colonies - in terms of number of cells per colony and area for OCT4 and SSEA3 positive cells. D) 
Percentage of OCT4 positive cells per colony vs percentage of SSEA3 positive cells per colony. 
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Figure 5.6 A) Frequency histograms for the percentage of SSEA3 and OCT4 positive cells per colony. B, C) 
Size of colonies - in terms of number of cells per colony and area for OCT4 and SSEA3 positive cells. D) 
Percentage of OCT4 positive cells per colony vs percentage of SSEA3 positive cells per colony. E) qPCR – 
Positive fraction (Blue), negative fraction (Orange) and unsorted culture (Green). Genes of endoderm 
(GATA6, SOX17), mesoderm (T, MIXL1) and ectoderm (OTX2, PAX6). 
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Figure 5.7 A) Frequency histograms for the percentage of SSEA3 and OCT4 positive cells per colony. B, C) 
Size of colonies - in terms of number of cells per colony and area for OCT4 and SSEA3 positive cells. D) 
Percentage of OCT4 positive cells per colony vs percentage of SSEA3 positive cells per colony. 
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3.2.5 Gene expression analysis in EC (NTERA2) cells 
The next step in the analysis of sorted fractions of the different Axordia antibodies was to 
look at the gene expression profile for each sorted population in order to see if any fraction 
possessed cells with a higher expression of a particular marker from the three germ layers 
(ectoderm, endoderm and mesoderm).  
The positive and negative populations of SSEA3 had lower expression of OCT4 than unsorted 
NTERA2 cells (Figure 4.8 E). There was no expression of the GATA6 and SOX17 markers in any 
population, either sorted or unsorted. The rest of the markers showed similar results, with 
the exception of OTX2 which is expressed in NTERA2 cells.  
OCT4 was more expressed in the positive fraction of AA11 and the other markers did not show 
considerable expression (Figure 4.1E). There was considerably more expression of OCT4 in 
the AG10 positive and negative fractions compared to a normal culture of NTERA2 cells. There 
was practically no expression of the rest of the markers in any culture, normal or sorted, 
except for OTX2. The negative fraction of AG10 did show some expression of the ectoderm 
marker PAX6 (Figure 4.2E). 
The positive and negative sorted populations of BF4 and CC9 displayed higher expression of 
OCT4 than normal NTERA2 cells (Figure 4.3; 4.4 E). Similar to the previous antibodies, there 
was no significant expression of any other markers of the three germ layers. However, CC9 
negative cells expressed PAX6 to some extent. 
The sorted fractions of CH8 had very low expression of any gene of interest (Figure 4.5 E) and 
the negative fraction of EF12 displayed some expression of PAX6 (Figure 4.6 E). 
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3.2.6 Gene expression analysis in ES cells (H7.S6) 
The expression of the genes of interest in ES cells was a little different from that found in EC 
cells. Markers of endoderm lineage seemed to be a little more expressed in some sorted 
populations, as well as some mesoderm markers. 
The positive fraction of AA11 had higher expression of OCT4 than the negative fraction. 
However, unsorted H7.S6 cells were found to express more OCT4 than both AA11 positive 
and negative populations (Figure 5 E). Likewise, the endoderm markers GATA6 and SOX17 
had a higher expression in unsorted ES cells. Mesoderm markers had similar expression across 
all three populations and the ectoderm markers SOX1 and PAX6 were more expressed in the 
positive fraction of AA11 compared to the negative and unsorted populations.  
The sorted fractions of AG10 displayed a similar pattern of expression of OCT4 as AA11 sorted 
cells and unsorted ES cells had higher expression of OCT4 than both sorted populations of 
AG10 (Figure 5.1 E). A similar pattern of expression of endoderm markers in AA11 sorted 
fractions was also seen in AG10, with the highest expression of these genes (GATA6, SOX17) 
found in unsorted ES cells. However, the negative fraction of AG10 had a higher expression 
of the mesoderm marker T than positive or unsorted cells. The same was observed for both 
ectoderm markers (SOX1 and PAX6). MIXL1 was more expressed in unsorted ES cells. 
In the case of BE12 sorted populations, very similar results to AA11 and AG10 were seen for 
the expression of OCT4 and the endoderm markers (Figure 5.2 E). However, it was the positive 
fraction of BE12 that displayed a higher expression of the mesoderm marker T. MIXL1 was 
similarly expressed in both the positive fraction and unsorted ES cells and higher than the 
negative population. In the case of the expression of ectoderm markers, the positive fraction 
displayed higher levels of SOX1 and PAX6 than the negative fraction and unsorted cells. 
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The positive and negative sorted populations of BF4 expressed less OCT4 than unsorted cells 
(Figure 5.3 E). However, BF4 negative cells had higher levels of SOX1 and T than unsorted ES 
cells. The positive population of CC9 expressed more OCT4 than the negative cells but was 
lower than unsorted ES cells (Figure 5.4 E). The endoderm markers had higher expression in 
the negative population of CC9 compared to its positive counterpart but lower than unsorted 
cells. CC9 negative cells also displayed more expression of MIXL1 than the positive fraction 
and unsorted cells. Expression of the ectoderm markers was very low in the three 
populations. 
The expression of OCT4 in EF12 positive cells was almost the same as in unsorted cells and 
the negative fraction had lower expression of this pluripotency marker (Figure 5.6 E). 
Endoderm expression was higher in the negative fraction and the same was also observed in 
the expression of mesoderm and ectoderm genes, although their expression was lower than 
GATA6 and SOX17. 
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3.3 Discussion 
The titration of the antibodies showed that overall the best response from standard and novel 
antibodies was seen when they were used at a 1:10 dilution. Many of the antibodies showed 
similar expression patterns (BF4 and CC9; CH8 and TRA-1-85) which suggested the possibility 
that the antibodies could be recognising similar antigens on the cell surface. 
In order to gain more insights into this possible scenario, analysis of the antigen expression 
patterns in human pluripotent stem cells was carried out. The data showed that all antibodies 
responded uniformly after each replicate and some differences could be seen from these 
experiments. The expression of SSEA1 seemed slightly higher in ES cells than in EC cells. 
However, AA11 had a lower expression in ES cells. Furthermore, BE12 had very low expression 
in NTERA2 and H7.S6 cells but it was highly expressed in nullipotent cells (N2102Ep). CC9, 
although present in all three cell lines tested, displayed a different distribution in each one of 
them. The only antibody that had very low reactivity in N2101Ep cells was DA9, where less 
than 30% of the cells were positive for this antibody. Moreover, DA9 showed a good response 
in NTERA2 cells but was practically non-existent in ES cells. The FACS expression profiles 
showed that there is heterogeneity in the stem cell population and so further analyses were 
carried out, such as clonogenic assays and gene expression assays. 
Overall, the cloning efficiency of the sorted fractions of the novel antibodies was similar to 
that of SSEA3 both in EC and ES cells (Figure 4 A-B). Also, the SSEA3 positive fraction cloned 
better in EC cells than its negative counterpart, whereas in ES cells both positive and negative 
fractions had the same cloning efficiency. Generally, the colonies from the sorted fractions of 
EC cells were bigger and had more content of SSEA3 and/or OCT4 than those of ES cells. When 
looking at the features of the colonies, such as their size and content of either SSEA3 or OCT4, 
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there were some novel antibodies that showed big differences when compared to SSEA3 
sorted fractions in both EC and ES cells. In EC cells, EF12, CH8, BF4 and AG10 were generally 
more dissimilar to the cells sorted for SSEA3 than the cells sorted for rest of the antibodies. 
Whereas in ES cells, the negative fractions of novel sorted antibodies tended to have low 
content of SSEA3 positive cells in their colonies compared to the negative fraction of SSEA3, 
with the exception of BE12. 
In EC cells, some colonies that formed from positive fractions of antigens had high levels of 
OCT4 expression, this suggests that such colonies were formed from undifferentiated cells. 
Furthermore, assessing the colonies for different features together with gene expression 
analysis helped in determining whether some novel antigens are useful in identifying different 
subsets of cells. For example, AG10, CC9 and EF12 showed interesting patterns of SSEA3/OCT4 
expression after replating. They displayed high levels of these markers, suggesting that the 
resulting colonies emerged from undifferentiated cells. Moreover, the genetic expression of 
lineage markers in these sorted fractions showed that there might be a bias towards specific 
lineages. AG10 positive cells, for example, had higher levels of MIXL1 than the unsorted and 
negative population, whereas the negative fraction of AG10 expressed SOX17 in higher levels. 
In the case of CC9, the negative fraction could potentially be biased towards an ectoderm 
lineage, and the positive fraction may be biased towards an endoderm lineage. Likewise, in 
EF12, the negative fraction might be biased to the ectoderm lineage. 
As speculated, there were many similarities but also quite a few differences between the 
colonies of sorted novel antibodies and those of SSEA3 sorted fractions. Hence, in order to 
further investigate how similar these novel antibodies might be to the already established set 
of standard antibodies and how they might help us further our understanding and power of 
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resolution of subsets of stem cells, the next step was to perform antigen competition assays 
to see if any of the novel antibodies recognised the same epitope on the surface of cells. 
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Chapter 4 
4 Competition assays between the novel set of antibodies and 
standard markers of cell differentiation 
 
4.1 Introduction 
 
Stage specific embryonic antigens are expressed as cell-surface molecules that display 
patterns of expression in a lineage-restricted manner during development. They are useful 
tools that help identify embryonic stem cells and their differentiated derivatives. Glycan 
epitopes such as SSEA1, SSEA3-4 and the glycoprotein antigens TRA-1-60; 1-81 have been 
used to identify and isolate specific cell types from heterogeneous populations and have been 
shown to undergo changes upon differentiation (Andrews et al., 1990) (Lanctot et al., 2007). 
The structure of SSEA3 and SSEA4 consists of 5-6 monosaccharides attached to a ceramide 
lipid tail (Figure 7) and they are one of the most commonly used markers to identify 
embryonic stem cells (Kannagi et al., 1983) (Muramatsu and Muramatsu, 2004). Their 
expression on the plasma membrane sees a rapid down-regulation upon differentiation 
(Fenderson and Andrews, 1992). Another commonly used marker of ES cells is the family of 
glycoprotein antigens (TRA-1-60; 1-81) which have been shown to recognise a keratan 
sulphated proteoglycan in a neuraminidase-sensitive and insensitive fashion, respectively 
(Badcock et al., 1999) (Andrews et al., 1984a). 
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 There is a relationship in the expression of surface molecules of the mouse embryo and 
human teratocarcinoma cells. In mouse, the changes that occur during the course of murine 
embryonic development have been well documented using immunological methods (Jacob, 
1977) (Solter and Knowles, 1979). Many of the antigens that are developmentally regulated 
are expressed by pre and peri-implantation mouse embryos and these in turn have also been 
found on the surface of murine teratocarcinoma cells (Kannagi et al., 1983). Human 
teratocarcinoma cell lines have been shown to express an antigen that is expressed on cells 
of the F9 murine teratocarcinoma cell line (Hogan et al., 1977) (Holden et al., 1977). Likewise, 
the monoclonal antibody defined antigen SSEA1, which is found on the 8-cell stage mouse 
embryo, was also found to be expressed on some cells of different human teratocarcinoma-
derived cell lines (Andrews et al., 1980). Nevertheless, SSEA1 is not explicitly found on the 
surface of human EC cells; instead it is majorly expressed on some differentiated derivatives 
of EC cells (Andrews et al., 1982) (Damjanov et al., 1982). SSEA3, however, is expressed on 
human EC cells and it is also an antigenic determinant found on zygote and cleavage-stage 
mouse embryos (Shevinsky et al., 1982). 
The identification of SSEA3 came about after immunizing a rat with 4 to 8 cell-stage mouse 
embryos. The monoclonal antibody derived from this immunization reacted with all 
preimplantation mouse embryos up to the early blastocyst stage. The reactivity of SSEA3 was 
Figure 7. Carbohydrate structure of SSEA3 & SSEA4. Modified from Andrews, P.W. 2011 
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found to be restricted to endoderm in early post-implantation embryos and to the kidney in 
adult mice (Fox et al., 1982). The subsequent analysis of the immunoprecipitates from murine 
embryos and human EC lines showed that molecules bearing SSEA3 were both glycolipid and 
glycoprotein, which suggested a carbohydrate antigenic determinant (Shevinsky et al., 1982). 
The derivation of an antibody recognising SSEA3 confirmed that immunization with embryos 
rather than with teratocarcinomas is also useful to define embryo-specific antigens.  
Soon after the derivation of SSEA3, another related stage-specific embryonic antigen (SSEA4) 
was reported and like SSEA3, was shown to be an epitope of a globolipid unique to human 
teratocarcinoma cells (Kannagi et al., 1983). Both of these antibodies were reactive with a 
unique globo-series ganglioside with the following structure: 
 
 
 
 
 
 
 
The terminal ‘a’ structure is recognised by MC813-70 (SSEA4), whereas the internal ‘b’ 
structure is recognised by the antibody MC631 (SSEA3). Further analysis of the reactivity of 
these two antibodies by solid-phase radioimmunoassay (RIA) determined that these 
antibodies recognise different antigenic determinants present on the same molecule and 
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despite their similar reactivity with cells and embryos tested by Kannagi and cols., MC813-70 
defines a novel stage-specific embryonic antigen (Kannagi et al., 1983). 
There are also several high molecular weight glycoprotein antigens expressed on human EC 
cells that are down-regulated upon differentiation. TRA-1-60 is one of these antigens that 
shares properties with other monoclonal antibodies like TRA-1-81, GCTM2 and K21 (Badcock 
et al., 1999). Whilst the EC cell marker antigens SSEA3 and SSEA4 are glycolipids, TRA-1-81, 
GCTM2 and K21 are monoclonal antibodies that recognise proteins of similar size to that 
identified by TRA-1-60; and they all display similar patterns of expression on tumour-derived 
cell lines (Andrews et al., 1984a) (Andrews et al., 1996). This family of high molecular weight 
protein antigens display some epitopes that appear to be human specific, but they have also 
been found in mouse embryos and mouse EC/ES cells (Muramatsu et al., 1978).  
Other commonly used markers include alkaline phosphatase (ALP) which is expressed in its 
tissue non-specific form in human EC and ES cells and is recognised by two antibodies, TRA-
2-49 and TRA-2-54 (Andrews et al., 1984c; Benham et al., 1981). Another couple of antigens 
used in the study of human EC and ES cells are CD9 and TRA-1-85. CD9 is typically expressed 
by human ES cells and is down-regulated upon differentiation. CD9 has also proved to be a 
valuable marker for identifying subsets of cells that still reside in the stem cell compartment 
(International Stem Cell et al., 2007; Laslett et al., 2007). TRA-1-85 recognises a pan-human 
antigen, also known as the blood group antigen Ok(a) (Williams et al., 1988). This antibody 
has been found to be expressed in several human cell lines and due to this widespread 
distribution has not been found to be useful in terms of identifying ES cell differentiation 
(Wright and Andrews, 2009). 
76 
 
Some of the novel antibodies described by Wright, et al., in 2011 have been shown to share 
similarities with some of the antibodies just described. For example, CH8 was shown to 
recognise CD9 (Wright et al., 2011). The other antibodies from the new panel have the 
potential to serve as new tools to help in the identification of subsets of stem cells. In the 
previous chapter, it was shown that sorting for specific populations that either expressed or 
lacked a particular antibody yielded patterns of gene expression that might insinuate that 
such sorted populations might be biased to a particular lineage. However, it might also be 
that these novel antibodies are recognising antigens already detected by one of the standard 
antibodies. Thus, in order to answer this question, competition assays were carried out 
against SSEA3 and TRA-1-60 in particular since they represent the most likely candidates for 
being duplicated.  
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4.2 Results 
SSEA3 was conjugated with a secondary antibody in order to carry out competition assays 
against the novel panel of antibodies. An initial titration curve of the conjugate antibody 
(SSEA3/AF647) was carried out and the FACS expression profiles were compared to standard 
SSEA3 (Figure 6 A-B). The concentration used was 1:10, the same used for the standard 
antibody in indirect staining. This initial titration assay showed that the optimal 
concentrations were in a similar range as the ones used for the standard SSEA3 antibody 
alone. Based on this first characterisation, the conjugation of the antibody with AF647 proved 
to have worked and a concentration of 1:50 seemed to be the ideal. 
A second titration curve was carried out where the dilutions used were less compared to the 
first one (Figure 6.1 A-B). In this case, the dilution at 1:100 for the conjugate antibody still 
gave a good response on N2102Ep cells and it was the concentration used for the subsequent 
competition assays against the novel antibodies. 
Next, the competition assay using the conjugate antibody (SSEA3/AF647) against SSEA4 and 
the novel panel of antibodies was performed (Figure 6.2). The median fluorescent intensity 
value was plotted against the dilution used for each competing antibody. In this first 
competition assay the dilutions used were 1:100; 1:50 and 1:10. SSEA4 displayed a notable 
drop in the value of median fluorescent intensity, suggesting that the antibody is recognising 
the same epitope as SSEA3 and out-competing it. This further establishes the existence of the 
reported similarity discussed previously between these two antibodies.  
In the case of the novel set of antibodies AA11, AG10 and BE12 did not alter the binding of 
SSEA3 in any form. The same was observed for the rest of the novel antibodies. EF12, 
however, showed a similar response to SSEA4, but the median fluorescent intensity suggests 
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that it did not outcompete SSEA3. Nevertheless, it is interesting to note that this is the only 
antibody from the novel panel that showed such a response. Thus, this first analysis suggests 
that the other antibodies are indeed recognising novel antigens on the cell surface. 
In a second assay performed against the same panel of antibodies, it was more evident that 
SSEA4 outcompeted SSEA3 and unlike the first assay, it did not take a great concentration of 
SSEA4 to displace SSEA3 from its binding site (Figure 6.3 & 6.4). The percentage of median 
fluourescent intensity dropped below 10% for all dilutions used of SSEA4 (Figure 6.4). On the 
other hand, the novel set of antibodies did not show such a decrease in their MFI (Median 
Fluorescent Intensity) values, except for EF12, whose MFI value did decrease to 15% when 
used at dilutions of 1:50 and lower (Figure 6.4). This raises the question of whether there 
might be some recognition of the same epitope as SSEA3 or perhaps just a segment of the 
epitope. In any case, the novel nature of the rest of the antibodies is further established by 
looking at this results. 
Next, competition assays with a TRA-1-60/AF488 conjugate antibody were performed (Figure 
6.5 A-B). The titration assay for this conjugate antibody was done on N2102Ep cells and it 
showed that there was still a good response from the antibody at low concentration (e.g. 
1:100), hence this was the concentration of conjugate antibody used for the subsequent 
competition assays. 
The first antibody to be compared with TRA-1-60/AF488 was TRA-1-85. The median 
fluorescent intensity of this antibody displayed a decrease when used at higher 
concentrations (Figure 6.6). However, it was not enough to show that it is competing with the 
conjugate antibody (Figure 6.7). SSEA4 also displayed a decrease in its median fluorescent 
intensity but unlike the competition assays against SSEA3/AF647 it was not enough to 
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demonstrate that it may be competing with SSEA3 for a binding site (Figure 6.6). The rest of 
the antibodies depicted in figure 6.6 did not show any kind of sign that they may be 
recognising the same epitope as TRA-1-60 which further suggests that they are novel tools 
that might help in identifying subsets of cells within the stem cell compartment. 
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Figure 6. A) SSEA3/AF647 conjugate antibody titration curve. Titration assay was done on N2102Ep cells 
plotted as dilution vs median fluorescent intensity. B) FACS expression profile histograms. Standard SSEA3 
was used at 1:10 dilution. 
 
 
 
 
 
 
 
 
 
A 
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Figure 6.1 A) SSEA3/AF647 conjugate antibody titration curve. Titration assay was done on N2102Ep cells 
plotted as dilution vs median fluorescent intensity. B) FACS expression profile histograms. Standard SSEA3 
was used at 1:10 dilution. 
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Figure 6.2 Competition Assay. N2102Ep cells were used and the median fluorescent intensity was plotted. 
AA11 1:10 (109.45); BE12 1:10 (135.94). Dilutions used were 1:10; 1:50 and 1:100. SSEA4 showed a clear 
competition with SSEA3 whereas none of the novel antibodies seemed to compete with SSEA3, except EF12 
which showed a slight inhibition. 
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Figure 6.3 Competition Assay of novel antibodies vs SSEA3/AF647. N2102Ep cells were used and the median 
fluorescent intensity was plotted for each competing antibody. Dilutions used were 1:5; 1:10; 1:50 and 1:100. 
Only SSEA4 and EF12 showed a more noticeable competition with SSEA3. 
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Figure 6.4 Competition Assay – Novel antibodies vs SSEA3/AF647. Median Fluorescence plotted as a 
percentage of median fluorescence intensity from N2102Ep cells stained with different dilutions from the 
competing antibody. MFI = Median Fluorescent Intensity. 
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Figure 6.5 A) TRA-1-60/AF488 conjugate antibody titration curve. Titration assay was done on N2102Ep 
cells plotted as dilution vs median fluorescent intensity. B) FACS expression profile histograms. Standard 
TRA-1-60 was used at 1:10 dilution. 
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Figure 6.6 Competition Assay of novel antibodies vs TRA-1-60/AF488. N2102Ep cells were used and the 
median fluorescent intensity was plotted for each competing antibody. Dilutions used were 1:5; 1:10: 1:50 
and 1:100. TRA-1-85 and SSEA4 showed a more noticeable competition with TRA-1-60. 
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Figure 6.7 Competition Assay – Novel antibodies vs TRA-1-60/AF488. Median Flourescence plotted as a 
percentage of median fluorescence intensity from N2102Ep cells stained with different dilutions from the 
competing antibody. MFI = Median Fluorescent Intensity. 
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4.3 Discussion 
The rationale behind these assays was to show that this novel panel of antibodies were 
different from previous standard set of antibodies used to identify cells in the stem cell 
compartment. Two of the most commonly used antibodies for this purpose are SSEA3 and 
TRA-1-60.  
It was important to show what relationship, if any, there was between the novel set of 
antibodies and the standard markers because the results shown in the previous chapter 
suggest that some of these antibodies might be capable of recognising subsets of cells within 
the bigger stem cell population. Having obtained such results, the next issue to address was 
to establish whether or not some of these antibodies were recognising the same binding site 
as the standard antibodies. 
Although these competition assays have shown that there is no competition for the epitope 
recognised by the standard antibodies and the novel panel, there was however, some degree 
of competition with EF12 and SSEA3. Further biochemical characterisation would be needed 
in order to establish a more direct relationship between these two antibodies. However, there 
was a clear competition between the antibodies recognising the antigens SSEA3 and SSEA4. 
The relationship between these two antibodies had already been suggested previously and 
these assays have further established such relationship. 
There is no doubt that further experiments showcasing more elaborate and definitive 
mechanisms of novel identification of subsets of cells by the novel antibodies would be 
needed. Such experiments had originally been contemplated in order to be included in this 
work, however, due to technical and some other external factors they could not be completed 
in time for inclusion. Some of the experiments envisaged included looking at lineage priming 
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of cells by replating sorted cells in differentiation conditions and analysing the cells after a 
given period of growth by qPCR and immunostaining assays. 
Moreover, there was a plan to assess the dynamics by which cells in different stem cell states 
interconvert by using high content clonogenic assays to test the capacity of subsets of cells 
identified with selected novel antibodies to revert to other substates within the stem cell 
compartment. 
Nevertheless, with these competition assays it is further established that the novel set of 
antibodies previously described by Wright et al., in 2011 might indeed be helpful in identifying 
subsets of cells within the stem cell compartment. 
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Chapter 5 
5 Discussion 
Nowadays, it is clear that stem cells are not homogeneous. Pluripotent stem cells are 
presented with a wide selection of pathways to choose from given their broad differentiation 
capacity. Being able to identify and mark stem cells in their undifferentiated state is crucial 
for selection of specific cell types. It is also important in trying to understand the 
particularities of cell fate choice since it would be possible to track stem cells as they make 
early commitment decisions.  Cell surface antigens present valuable tools for marking cells, 
not only because of their sensitivity but also because they can be used to mark and to isolate 
individual viable cells for functional tests. 
A number of well characterised antibodies have been widely used previously to analyse 
differentiation of human Pluripotent Stem Cells.  In this study I have carried out a further 
analysis and characterisation of the novel antibodies recently described by Wright and cols. 
in 2011 (Wright, et al., 2011). Notably, I have found that this novel group of antibodies may 
be helpful in identifying subsets of cells that were not being recognised by standard 
antibodies. For example, in EC cells, AG10, CC9 and EF12 showed interesting patterns of 
SSEA3/OCT4 expression after sorting for their respective positive and negative populations. 
They displayed high levels of SSEA3 and OCT4, suggesting that the resulting colonies emerged 
from undifferentiated cells.  
Furthermore, gene analysis expression showed that there might be a bias towards specific 
lineages. The high levels of MIXL1 expression in the positive fraction of AG10 is indicative of 
this, since the unsorted and negative population of AG10 lacked high expression for this gene. 
91 
 
Nevertheless, the negative fraction of AG10 expressed SOX17 in higher levels, suggesting an 
endoderm bias for the AG10 negative cells. In the case of CC9, the negative subpopulation 
showed a potential bias towards an ectoderm lineage, whereas the positive fraction might be 
biased towards an endoderm fate. EF12 negative cells had higher expression of ectoderm 
marker PAX6. 
However, it was speculated that some of the novel antibodies could recognise similar 
epitopes to the ones identified by commonly used standard markers. Previous biochemical 
characterisation done on the novel antibodies had indeed shown a possible relationship in 
the structures of some antibodies, namely, AG10 and EF12 being suggested as part of the 
family of glycolipids related to SSEA3 and SSEA4; and CC9 being related to the TRA family of 
glycoproteins (Wright, et al., 2011). 
The competition assays performed in this study helped to further clarify whether there were 
any instances in which any of the novel antibodies were competing for binding sites 
recognised by standard antibodies for SSEA3 and TRA-1-60. Notably, it was found that there 
was a marked competition between the antibodies that recognise the antigens for SSEA3 and 
SSEA4. This is in agreement with previous studies that had established a relationship between 
these two markers, as the epitopes were identified as different trisaccaharide elements 
contained within a common glycolipd, sialyl-gal-globoside.  In that case the SSEA4 epitope is 
dependent on the terminal sialic acid moiety, whereas SSEA3 is not (Kannagi, et al., 1984).  
However, direct competition assays between the antibodies recognising SSEA3 and SSEA4 
have not been previously reported. 
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The possibility that the novel antibodies recognise the same epitopes associated with the 
commonly used markers was questioned when they were first derived a few years ago, but it 
was not analysed. Therefore, by analysing their similarities with the existent set of standard 
antibodies, this project has helped build a more strong and coherent insight into the benefits 
that identifying new subsets represent. Out of the whole panel of novel markers, only EF12 
appeared to be able to compete with the anti-SSEA3 antibody for binding to human EC cells, 
suggesting that like SSEA3 and SSEA4, the EF12 epitope is associated with the same 
globoseries glycolipid.  It would be interesting to further investigate how closely related the 
antibodies for SSEA3 and EF12 are by looking at their chemical structure and identify precisely 
which region(s) is being recognised with the same epitope. 
However, none of the novel antibodies was able to compete with TRA-1-60. Nevertheless, 
there was some evidence where the antibody recognising SSEA4 showed a certain degree of 
inhibition of the binding of the TRA-1-60 antibody, even though the SSEA4 epitope is 
associated with the globoseries glycolipd, sialyl-gal-globoside (Kannagi et al., 1984), whereas 
TRA-1-60 is associated with a high molecular weight proteoglycan (Badcock et al., 1998).  
Nevertheless the epitope in both cases includes a sialic acid moiety and it is possible that this 
is the basis for some limited cross reactivity. 
The results from the current study have shown that the novel antibodies described by Wright 
et al (2011) are potentially valuable new tools, able to identify ES cell markers mostly distinct 
from the already well-established set of surface antigens.  Further, even if there is a 
competition for the same binding site between the antibodies for SSEA3 and EF12, they could 
be useful by complementing each other just as TRA-1-81 and TRA-1-60 (Andrews, et al., 1984) 
have proved to be valuable either alone or in combination.  In future these markers are likely 
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to be useful to define potentially lineage biased substates of human ES cells which in turn 
could lead to more plausible strategies for enrichment of specific cell types needed for 
regenerative medicine. 
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